Correction to: Cost-effectiveness analysis of umeclidinium bromide/vilanterol 62.5/25 mcg versus tiotropium/olodaterol 5/5 mcg in symptomatic patients with chronic obstructive pulmonary disease: a Spanish National Healthcare System perspective

Detalles Bibliográficos
Autores principales: Driessen, M. T., Whalen, J., Buguth, B. Seewoodharry, Vallejo-Aparicio, L. A., Naya, I. P., Asukai, Y., Alcázar-Navarrete, B., Miravitlles, M., García-Río, F., Risebrough, N. A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Correction
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6348614/
https://www.ncbi.nlm.nih.gov/pubmed/30691468
http://dx.doi.org/10.1186/s12931-019-0985-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6348614/
https://www.ncbi.nlm.nih.gov/pubmed/30691468
http://dx.doi.org/10.1186/s12931-019-0985-2

Ejemplares similares